Transplant scientist Camillo Ricordi

Transplant scientist Camillo Ricordi

Healthcare

Camillo Ricordi’s Forty-Year Fight Against Diabetes: "Dad, Callas and the Singer-Songwriters. By the Fireplace, I Found the idea"

The transplant scientist, son of the record label founder: "My life from Milan to America. Today the real challenge is prevention"

Valeria Robecco

New York - The pancreas arrived on a Friday evening in 1986 at Paul Lacy's laboratory at Washington University in St. Louis. Eighteen hours of ischemia: too old, not worth a night's work. It ended up in the trash. A young doctor from Milan waited for everyone to leave, retrieved it, and worked until dawn with a chamber of his own invention. On Saturday morning, Camillo Ricordi called Lacy to the microscope: under the lens were hundreds of thousands of intact pancreatic islets, the microscopic organs that contain insulin-producing cells.

Forty years later, the Ricordi Chamber, a device that separates the insulin-producing islets from a donor pancreas without damaging them so they can be transplanted into people with type 1 diabetes, is the global standard, used in more than 50 countries. Its inventor, Director Emeritus of the Diabetes Research Institute in Miami, was born in New York, but by the time he was three months old he was already in Milan. His father, Nanni Ricordi, was heading home to produce the first record of Maria Callas at La Scala. That album marked the birth of Dischi Ricordi, the label he founded, which went on to launch Italy's great singer-songwriters.

How does a boy who grew up in recording studios end up trying to cure diabetes? Speaking to La Stampa USA, Ricordi answers with the name of his maternal grandfather. "Emilio Fachini had three degrees, in engineering, physics and medicine, and on his large estate there was a stable turned into a laboratory. At the dinner table he would give me problems to solve without telling me the answer. 'Come back when you have the solution,' he'd say. He instilled in me the bug of curiosity." He dreamed of astrophysics, until a book on the brain by Nobel laureate John Eccles led him to medical school to study neuroscience. When he graduated, his young cousin Serena was diagnosed with type 1 diabetes. "I told myself: I'll cure diabetes, and in two years I'll go back to neuroscience." More than forty years have passed.

The idea came to him in front of a fireplace, watching ashes rise up the chimney. "People had been trying since the 1960s. The pancreas is a solid organ containing a few drops of a very special load: hundreds of thousands of scattered microscopic insulin-producing structures that have to be separated intact from the surrounding tissue. I thought it could be possible to gently disassemble the organ, with enzymes injected into the ducts that are connected to 98% of the organ, but not to the islets, and progressively release them in a continuous flow." To build it, he went to America. "At Washington University in St. Louis there were Rita Levi-Montalcini and a dozen Nobel laureates. You just work, because there's nothing else around."

In 1989 he returned to Milan to transfer the technology and perform the first transplants, but the hospital preferred to let the Americans go first. Then Thomas Starzl called from Pittsburgh. "To me he was the Greek god of transplantation. He told me: your name is at the top of the list provided by the Chair of the Nobel Assembly in Stockholm, you have 24 hours to decide and one week to move, should you accept this mission. It was just before Christmas, and I left with my Chamber. On January 10, 1990, he called me: I have a pancreas for you." It was the first in a series of successful islet transplants in human beings; the results were published in The Lancet that August.

And those first patients? "You become friends with every family. I spoke with Antonella, one of the first, just the other day."

In 1993 Ricordi moved to Miami, where for over thirty years he led the Diabetes Research Institute, of which he is now Director Emeritus. At the University of Miami he is Chief of the Division of Cellular Transplantation and directs the DRI's Cell Transplant and Regenerative Medicine Center. For more than a decade he chaired the steering committee of the eight-center North American consortium that in 2017 completed the first NIH-funded, FDA-approved phase 3 trial of islet transplantation. He has authored 1,250 scientific publications, cited more than 66,000 times, and holds 28 patents. His honors number more than a hundred: the World Prize in Surgery in 2001, the American Diabetes Association's Outstanding Scientific Achievement Award in 2002, Officer of the Order of Merit of the Italian Republic in 2009, and the Leonardo da Vinci Prize in 2023, received in Taormina alongside two Nobel laureates, Shinya Yamanaka and Gregg Semenza.

For his patients, Ricordi is willing to bend the rules. In 2009 the chief of general surgery at Walter Reed Army Medical Center called him: an airman of Italian descent, shot in the back in Afghanistan, had a shattered pancreas. Could the islets be saved? The university said no: there was no FDA approval. "I told Washington to send what they could save of the injured organ. It was the night before Thanksgiving." The young man never needed insulin again.

The next goal is to free patients from anti-rejection drugs. Tegoprubart, a new molecule being tested in islet transplants in a collaborative effort between Chicago and Miami, is a step in that direction, replacing a toxic immunosuppressive drug. For 2027 he is preparing the first islet transplants protected by a tolerance-inducing microgel, while collaborating to bring to the clinic a novel strategy that makes islets invisible to the immune system, to avoid anti-rejection drugs.

Today his fight against diabetes also means prevention. Why? "I can do ten thousand transplants a year, but there were 171 million people with diabetes in 2000, and today there are 589 million." Through AION Healthspan, the regenerative medicine company he co-founded, he works with leading clinical-stage centers, including Stanford and the Mayo Clinic, to reverse chronic diseases associated with accelerated aging at an early stage, when health can still be restored.

That is how a transplant surgeon came to focus on healthspan. "An exclusively reactive healthcare system, one that steps in only once disease has arrived, becomes progressively unsustainable," he says. His model has four levels: predictive diagnostics, enhanced by artificial intelligence, to uncover and neutralize invisible risk factors years before they progress into disease; early intervention at the first symptoms; advanced therapies for those already ill, "so that no one is left behind"; and preventing disease from returning after an initially successful cure. Beyond the health benefits, the model makes economic sense: a study published in Nature Aging estimated that one additional year of healthy life would be worth $38 trillion in the United States alone. According to Ricordi, it could deliver significant savings for health systems while freeing resources to develop advanced treatments for severe and rare diseases.

He has never cut his ties to Italy. Since 2004 he has chaired the board of ISMETT, the transplant institute in Palermo; he led the Ri.MED Foundation, served on Italy's Superior Health Council, and in 2025 received the PAIR, the Prize for American-Italian Relations. His books on healthy longevity, The Healthspan Code and Therapeutic Revolution, were first published in Italian by Mondadori and then in updated English editions.